drugset / Trial / NCT03166189
Autologous Bone Marrow-derived Mesenchymal Stem Cells for Atrophic Endometrium in Patients With Repeated IVF Failures
Phase 2
Completed
46 enrolled
D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology
RandomizedParallel-groupOpen-labelTreatment
Summary
Investigators will examine safety and efficiency of the cell product of autologous bone marrow-derived mesenchymal stem cells (MSC) for patients with repeated IVF failures and hypoplastic or/and fibrosis process of endometrium
Timeline
- Start
- 2017-12-20
- Primary completion
- 2019-03-16
- Completion
- 2019-12-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | bone marrow-derived MSC | Cell therapy | 5e+06 cells | Other |
| Background | Dydrogesterone | Other / unclassified | 20 mg | — |
| Background | estradiol valerate | Unknown | 4 mg | — |